Current strategies for the treatment of complicated intraabdominal infections.

abstract：IMPORTANCE OF THE FIELD:The emergence of fixed-combination drugs for the treatment of glaucoma has, to some extent, changed the medical management of glaucoma. The potential benefits of these drugs include a reduction in the total number of drops and preservatives instilled per day and improved patient comfort factors,...

journal_title：Expert opinion on pharmacotherapy

authors： Razeghinejad MR,Sawchyn AK,Katz LJ

更新日期：2010-04-01 00:00:00

abstract：INTRODUCTION:Inhaled corticosteroids (ICS) alone or in combination with an inhaled long-acting beta2-agonist (LABA) are the preferred long-term treatment for adults and adolescents with symptomatic asthma. Additional drugs include leukotriene-receptor antagonists, slow-release theophylline and the long-acting muscarini...

journal_title：Expert opinion on pharmacotherapy

authors： Thomson NC

更新日期：2017-02-01 00:00:00

abstract：:Developments in the role of adjuvant and neoadjuvant chemotherapy for the treatment of patients with breast cancer have focused on the taxes, in particular, docetaxel. This paper discusses the rationale for the introduction of docetaxel into the management of patients following surgery and also its role in those patie...

journal_title：Expert opinion on pharmacotherapy

authors： Heys SD,Sarkar T,Hutcheon AW

更新日期：2004-10-01 00:00:00

abstract：:Osteosarcoma is the most frequent primary cancer of bone. When treated by surgery alone, it is almost invariably followed by metastatic dissemination and death. This dismal prognosis can be improved dramatically by including chemotherapy in an interdisciplinary regimen. Today, two-thirds of patients with localised ext...

journal_title：Expert opinion on pharmacotherapy

authors： Bielack SS,Machatschek JN,Flege S,Jürgens H

更新日期：2004-06-01 00:00:00

abstract：INTRODUCTION:Pharmacological treatment plays a major role in the management of advanced, persistent or recurrent uterine leiomyosarcoma (LMS), whereas its usefulness in the adjuvant setting is still debated. A thorough literature search was undertaken using the Pubmed databases. Systematic reviews and controlled trials...

journal_title：Expert opinion on pharmacotherapy

authors： Gadducci A,Guerrieri ME

更新日期：2015-02-01 00:00:00

abstract：:Maximal surgical debulking and radiotherapy have been the cornerstone of therapy for high-grade gliomas. The impact of chemotherapy on outcome has been marginal and, until recently, its usage has been debatable. The development of new drugs and an improved understanding of chemoresistance have reinvigorated interest i...

journal_title：Expert opinion on pharmacotherapy

authors： Cavaliere R,Newton H

更新日期：2006-04-01 00:00:00

abstract：INTRODUCTION:Status Epilepticus (SE) is the most common neurological emergency of childhood. It requires prompt administration of appropriately selected anti-seizure medications. Areas covered: Following a distinction between estabilished and emergent drugs, we present pharmacological treatment options and their clinic...

journal_title：Expert opinion on pharmacotherapy

authors： Verrotti A,Ambrosi M,Pavone P,Striano P

更新日期：2017-06-01 00:00:00

abstract：:Candesartan is a long-acting angiotensin receptor antagonist that is well absorbed from the gastrointestinal tract, with insurmountable receptor binding abilities. Recent studies have shown candesartan to be an effective therapy for heart failure patients, producing a significant reduction in mortality and morbidity. ...

journal_title：Expert opinion on pharmacotherapy

authors： McKelvie RS

更新日期：2006-10-01 00:00:00

abstract：:The burden of insomnia has had a significant effect not only on the socioeconomic matrix, but also the medical terrain, as signified by the increased morbidity and mortality of its associated psychiatric and organic sequelae. To this end, a plethora of pharmacotherapeutic agents have been recently introduced that addr...

journal_title：Expert opinion on pharmacotherapy

authors： Navab P,Guilleminault C

更新日期：2006-09-01 00:00:00

abstract：:An increasing need for economic evaluations of non-Hodgkin's lymphoma (NHL) treatments exists. We performed a literature review on the currently available NHL economic evaluations, using PubMed and the Cochrane database. English and Dutch language papers on treatment in adults were selected. A total of 88 publications...

journal_title：Expert opinion on pharmacotherapy

authors： van Agthoven M,Uyl-de Groot CA,Sonneveld P,Hagenbeek A

更新日期：2004-12-01 00:00:00

abstract：:Therapy of hepatitis C virus (HCV) infection may prevent progression to cirrhosis, hepatocellular carcinoma and end-stage liver disease. The cornerstone of treatment has long been standard IFN-alpha, the use of which was associated with a sustained biochemical and viral response in only a small proportion of patients....

journal_title：Expert opinion on pharmacotherapy

authors： Toniutto P,Fabris C,Pirisi M

更新日期：2006-10-01 00:00:00

abstract：INTRODUCTION:Antifungal resistance is an emerging problem that increases morbidity and mortality in immunosuppressed pediatric patients, who suffer from invasive fungal diseases. Optimal pharmacological management is critical for the successful treatment of invasive fungal infections by resistant strains. AREAS COVERE...

journal_title：Expert opinion on pharmacotherapy

authors： Stergiopoulou T,Walsh TJ

更新日期：2015-02-01 00:00:00

abstract：INTRODUCTION:Intravenous (I.V.) morphine administered through a patient-controlled system currently represents the gold standard treatment for moderate to severe acute postoperative pain. To fix the limitations showed by the available I.V. patient-controlled analgesia (PCA) systems that may restrict its use in the clin...

journal_title：Expert opinion on pharmacotherapy

authors： Fanelli A,Sorella MC,Chelly JE

更新日期：2016-01-01 00:00:00

abstract：:Diabetes mellitus has reached epidemic proportions in many countries and is the most common cause of end stage renal disease (ESRD). The angiotensin II receptor-1 (AT(1)) antagonists losartan and irbesartan have recently been evaluated as renoprotective agents in large clinical trials of patients with Type 2 diabetes ...

journal_title：Expert opinion on pharmacotherapy

authors： Doggrell SA

更新日期：2002-05-01 00:00:00

abstract：:Non-motor symptoms may considerably reduce parkinsonian quality of life, particularly in advanced stages of the disease. Autonomic features, such as seborrhoea, hyperhidrosis, orthostatic hypotension, excessive salivation, bladder dysfunction and GI disturbances, and neuropsychiatric symptoms, such as depression, slee...

journal_title：Expert opinion on pharmacotherapy

authors： Müller T

更新日期：2002-04-01 00:00:00

abstract：:Introduction: This clinical guidance looks at the specific concerns of delivery of medical treatment for people with epilepsy and intellectual disability (ID). People with ID have not been included in licensing drug trials of AEDs. However, this population has an over-representation of seizure comorbidity, treatment r...

journal_title：Expert opinion on pharmacotherapy

authors： Watkins L,O'Dwyer M,Kerr M,Scheepers M,Courtenay K,Shankar R

更新日期：2020-02-01 00:00:00

abstract：:ABSTARCT Introduction: Cardiovascular disease (CVD) continues to be an essential cause of morbidity and mortality among people living with human immunodeficiency virus infection (PLWH). Since the bulk of cardiovascular risk (CVR) factors are shared between PLWH and the general population, prevention and treatment stra...

journal_title：Expert opinion on pharmacotherapy

authors： Corbacho N,Mur I,Molas ME,Vidal F,Domingo P

更新日期：2021-01-04 00:00:00

abstract：INTRODUCTION:Adjunctive pharmacotherapy is of key importance in determining the outcomes of percutaneous coronary intervention (PCI). In parallel, there has been an increasing body of evidence indicating that the aggressive management of coronary risk factors and changes in lifestyle behavior yield additional positive ...

journal_title：Expert opinion on pharmacotherapy

authors： Capodanno D,Tamburino C,Dangas G

更新日期：2011-05-01 00:00:00

abstract：:Insulin glulisine (Apidra, Sanofi-Aventis), a new and recently approved rapid-acting insulin analogue, mimics the pharmacokinetic and pharmacodynamic profiles of physiological human insulin, but has a rapid onset, peak effect at 1h, and a shorter duration of action (approximately 4 h). Its rapid-action properties are ...

journal_title：Expert opinion on pharmacotherapy

authors： Garg SK,Ellis SL,Ulrich H

更新日期：2005-04-01 00:00:00

abstract：INTRODUCTION:Radioiodine [RAI]-resistant advanced and progressive differentiated thyroid cancer [DTC], although rare, constitutes a real challenge as its prognosis is poor and available therapeutic options, until now, have been limited. Discovery of a crucial role of distinct tyrosine kinases in DTC pathogenesis opened...

journal_title：Expert opinion on pharmacotherapy

authors： Krajewska J,Kukulska A,Jarzab B

更新日期：2016-08-01 00:00:00

abstract：INTRODUCTION:Overactive bladder (OAB) is a common condition that has a profound impact on an individual's overall health and quality of life. Muscarinic receptor antagonists are the mainstay of oral pharmacotherapy for OAB. While all of the medications in this class are significantly more effective than placebo, they a...

journal_title：Expert opinion on pharmacotherapy

authors： Gomelsky A,Dmochowski RR

更新日期：2012-06-01 00:00:00

abstract：:Efavirenz is a non-nucleoside reverse transcriptase inhibitor that in most treatment guidelines is recommended to be taken combined with two nucleoside analogue reverse transcriptase inhibitors, as a preferred first-line regimen for the treatment of HIV-1 infection. The antiretroviral efficacy of efavirenz-based combi...

journal_title：Expert opinion on pharmacotherapy

authors： Vrouenraets SM,Wit FW,van Tongeren J,Lange JM

更新日期：2007-04-01 00:00:00

abstract：:Lapatinib is a dual (ErbB-1 and ErB-2) receptor tyrosine kinase inhibitor (TKI) that was recently approved by the FDA for the treatment of advanced breast cancer. It shows synergy with trastuzumab, and has demonstrated clinical activity in trastuzumab-resistant tumour. This paper reviews the drug development of lapati...

journal_title：Expert opinion on pharmacotherapy

authors： Mukherjee A,Dhadda AS,Shehata M,Chan S

更新日期：2007-09-01 00:00:00

abstract：INTRODUCTION:Tubulin inhibitors including taxanes and vinca alkaloids are important components of chemotherapy regimens used in advanced non-small cell lung cancer (NSCLC). Despite a treatment paradigm shift due to molecularly-targeted therapies and immunotherapy, a majority of patients will receive chemotherapy during...

journal_title：Expert opinion on pharmacotherapy

authors： Hardin C,Shum E,Singh AP,Perez-Soler R,Cheng H

更新日期：2017-05-01 00:00:00

abstract：:Desvenlafaxine (DESV) is a newer antidepressant, which inhibits serotonin-norepinephrine reuptake neurotransmission, similarly to venlafaxine, milnacipran and duloxetine. It was approved in February 2008 by the FDA for the treatment of major depressive disorder (MDD), based on well-controlled and adequately powered, l...

journal_title：Expert opinion on pharmacotherapy

authors： Pae CU

更新日期：2011-12-01 00:00:00

abstract：:Gonorrhea remains an important clinical and public health problem throughout the world. Gonococcal infections have historically been diagnosed by Gram stain and culture but are increasingly diagnosed through nucleic acid tests, thereby eliminating the opportunity for antimicrobial susceptibility testing. Gonococcal in...

journal_title：Expert opinion on pharmacotherapy

authors： Barry PM,Klausner JD

更新日期：2009-03-01 00:00:00

abstract：BACKGROUND:This study investigated the safety and efficacy of metformin up-titration in Japanese patients with type 2 diabetes mellitus treated with vildagliptin (100 mg/day) and low-dose metformin (500 or 750 mg/day). RESEARCH DESIGN AND METHODS:Fifty patients were randomly allocated to the control group (maintaining...

journal_title：Expert opinion on pharmacotherapy

authors： Suzuki L,Kanazawa A,Uzawa H,Osonoi Y,Masuyama A,Azuma K,Takeno K,Takayanagi N,Sato J,Someya Y,Komiya K,Goto H,Mita T,Ikeda F,Ogihara T,Shimizu T,Ohmura C,Saito M,Osonoi T,Watada H

更新日期：2017-12-01 00:00:00

abstract：BACKGROUND:Pegaptanib sodium, the first aptamer therapeutic approved for use and the first antiangiogenic agent used to treat ocular neovascular disease, acts by inhibiting the 165 isoform of vascular endothelial growth factor believed primarily responsible for pathologic ocular neovascularization and vascular permeabi...

journal_title：Expert opinion on pharmacotherapy

authors： Apte RS

更新日期：2008-02-01 00:00:00

abstract：:The recently published Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) assessed the efficacy and safety of abaloparatide (80 µg daily subcutaneous) (ABL) vs placebo during 18 months, in postmenopausal osteoporosis. Teriparatide (20 µg daily subcutaneous) (TPD) was used as an open label active comparator...

journal_title：Expert opinion on pharmacotherapy

authors： Reginster JY,Al Daghri NM,Bruyere O

更新日期：2017-12-01 00:00:00

abstract：INTRODUCTION:Patients with advanced pancreatic cancer (APC) refractory to first-line therapy have a dismal prognosis and limited therapeutic options, with only one option consisting of nanoliposomal irinotecan in combination with fluorouracil and folinic acid which was approved by FDA based upon results of the phase II...

journal_title：Expert opinion on pharmacotherapy

authors： Passero FC Jr,Saif MW

更新日期：2017-10-01 00:00:00